Prof Roy Gerona UCSF monitoring for New Psychoactive Substances (NPS) скачать в хорошем качестве

Prof Roy Gerona UCSF monitoring for New Psychoactive Substances (NPS)

The rapid emergence of a large number of NPS (New Psychoactive Substances) on the global drug market poses a significant risk to public health and a challenge to drug policy. Dr. Ana Najafi, the Director of Strategic Pharmaceutical Development at Emery Pharma, introduces Professor Roy Gerona is an expert in bioanalysis and mass spectrometry techniques to monitor environmental chemicals, including new psychoactive substances (NPS) and drugs of abuse. He collaborates with poison centers, medical examiner's offices, and government agencies like the DEA and CDC. Dr. Gerona shares his journey of establishing a lab and acquiring funding for his research. His lab focuses on NPS analysis, endocrine-disrupting chemicals, and drug adherence monitoring using liquid chromatography-tandem mass spectrometry (LC-MS/MS) and high-resolution mass spectrometry (HRMS). Dr. Gerona discusses his involvement in the Drug Enforcement Administration (DEA) toxicology testing program, which aims to detect and identify new psychoactive substances in biological samples, especially in cases involving intoxications or deaths. The program collaborates with referral institutions that provide samples for analysis. The lab uses a comprehensive reference library and employs targeted, suspect screening, and non-targeted analysis to identify and quantify substances in the samples. Collaboration with the University of Sydney has enabled Dr. Gerona's lab to predict potential new synthetic cannabinoids. The workflow includes screening, confirmation, and quantitation. Cases are sourced from various regions in the United States, with a focus on detecting emerging NPS. The lab's methods and strategies are tailored to each case, and collaboration with medical examiner offices and poison centers is vital. Despite challenges, the lab's work contributes to understanding and addressing the presence of NPS in various contexts. For more information contact Emery Pharma. About Emery Pharma: Emery Pharma is a full-service contract research laboratory, supporting the end-to-end development of small molecule drugs, biologics, biosimilars, gene therapy, botanicals, and more. Emery Pharma's premium services include analytical, bioanalytical solutions, microbiology & cell biology services, drug and impurity characterization, and general R&D and cGMP/GLP support. At Emery Pharma, our focus is to find innovative solutions for our Clients’ toughest challenges and tailoring those solutions to fit each Client’s unique needs. Our experienced scientific team will manage the process: from drug discovery, proof-of-concept, data management, data analysis, to gathering insights. The team excels at solving scientific challenges, and addressing any issues early in the process, so Clients don’t experience unnecessary setbacks. Emery Pharma’s experienced chemists and biologists deploy state-of-the-art technology. Instrumentation ranges from high-resolution mass spec (Orbitrap), Triple quad LC-MS/MS, GC-MS, Preparative HPLC, and 400 MHz multinuclear NMR. Contact us: [email protected] https://emerypharma.com/ keywords: Dr. Ana Najafi Emery Pharma Dr. Roy Gerona Bioanalysis Mass spectrometry techniques Environmental chemicals New psychoactive substances (NPS) Drugs of abuse Poison centers Medical examiner's offices Government agencies DEA toxicology testing program Liquid chromatography-tandem mass spectrometry (LC-MS/MS) High-resolution mass spectrometry (HRMS) Endocrine-disrupting chemicals Drug adherence monitoring Synthetic cannabinoids Targeted analysis Suspect screening Non-targeted analysis Reference library Biological samples Drug detection Medical examiner collaboration Poison center collaboration